Corporate

Mahindra Satyam down 7% on L&T's stake sale

Mahindra Satyam slipped to a low of Rs 109 and finally ended at Rs 110, down around 7%. The counter witnessed trades of 46.44 million shares on the BSE as compared to the two-week daily average traded volumes of 7.23 million shares. - Ranbaxy up on WHO"s nod for AIDS drug - IT stocks in demand as acquistion clicks - Shree Renuka at new 52-wk high on overseas acquisition - Punj Llyod erases gains, ends down 2% - Pyramid hits 10% lower circuit on Sebi ban - Sun Pharma gains on HC order Larsen & Toubro on the other hand ended flat at Rs 1,643 and clocked volumes of 291,251 shares at the counter. ____________________________________________ (Updated at 1056hrs) Mahindra Satyam has declined today following the news that Larsen & Toubro is selling a third of its 6.9% stake in the company. The stock opened at Rs 114 and slipped in the negative zone to touch a low of Rs 109. The stock is now trading at Rs 112, down 5% from the previous close. The counter has clocked huge volumes of 35.53 million shares as compared to the two-week daily average traded volumes of 7.23 million shares on the BSE. Larsen & Toubro on the other hand is trading flat Rs 1,651. The counter has witnessed trades of 94,903 shares on the BSE. Click here to read more: L&T to sell a third of Satyam stake


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

News of the day
Nirma's 'controversial' cement project gets government nod
Gujarat government has given its green signal to Nirma Ltd"s controversial cement plant in Mahuva. The company has been aiming to foray into cement production by setting up a 2.4 million tonnes cement plant in Bhavnagar district for an estimated investment of Rs 1000 crore, according to industry sources privy to the development.
Popular Articles

Latha Jishnu: The campaign against that pesky 3 (d)
For the Americans (and some Europeans) it’s “that pesky section”. And the US government is throwing its weight behind an industry campaign to discredit this section if not get it removed from India’s Patent Act. Yes, of course, it is Section 3(d) that is under attack from big pharma which has lost no opportunity in pointing out that this law will stifle the growth of India’s own drug companies and also choke off foreign investment in the sector. In recent weeks, this campaign has picked up in tempo both here and abroad.

Isro looking at 25 per cent revenue growth
The Indian Space Research Organistaion (Isro) is looking at 25 per cent growth in revenues this fiscal over Rs 1,000 crore attained last year, betting big on satellite launches and carrying space crafts of other countries.